Is It Too Late to Buy HealthEquity Inc (HQY) After 3.2% Rally? G

HealthEquity (HQY) reported Q2 2027 revenue growth of 8% YoY, up from 7%, with adjusted EBITDA rising 11% to $167M. HSA accounts grew 24% YoY to 202K, and total HSA assets reached $37.9B. Management raised full-year guidance, but noted pricing pressure and GAAP net income was $65.6M.

HealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.

HealthEquity reported Q2 revenue of $350.7M, up 8% YoY. Adjusted EBITDA rose 11% to $167M, with a record margin of 48%. HSA assets grew 14% to $37.9B. Net income increased 10% to $65.6M. The company raised fiscal 2027 guidance, citing strong execution and operating leverage.

HealthEquity (HQY) stock fell 8.6% this week despite beating earnings and revenue estimates for Q2. The company reported adjusted EPS of $1.24 on revenue of $350.7M, up 15.7% and 7.6% YoY, respectively. Investors expected stronger guidance, as the company only slightly raised its full-year revenue target and reiterated EPS guidance.

HealthEquity (HQY) stock rose 3.2% to $96.37 after Q2 results showed record adjusted EBITDA margin of 48%, revenue up 7.6% to $350.7M, and net income up 9.7% to $65.6M. Bulls highlight cost reductions and growth in HSA accounts, while bears caution on interest rate risks and pricing pressures. The company raised FY2027 guidance.

HealthEquity (HQY) reported Q2 net income of $65.6M ($0.78 EPS) and revenue of $350.7M, beating estimates. A DCF model suggests 48% upside, valuing shares at $179, despite mixed market multiples. Full-year guidance is $4.66-$4.73 EPS on $1.41B-$1.42B revenue. Investors debate the durability of the company's free cash flow.